Dr. Christoph Massner is a Principal at Earlybird Venture Capital's Health Fund, specialising in digital health, medical devices, diagnostics, R&D platform technologies, and biopharma. He currently sits on the boards of Wellabe, Ariceum Therapeutics, and Noscendo, and serves as a board observer for Alesi and Shape Memory Medical. Prior to joining Earlybird in 2018, Christoph spent 7+ years conducting research in various laboratories in Germany and Australia and earned his PhD in Synthetic Biology from the Technical University of Munich (TUM).